|
Myocardial Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Cardioplegia prevents ischemia-induced transcriptional alterations of cytoprotective genes in rat hearts: a DNA microarray study.
|
16214533 |
2005 |
|
Hepatoma, Morris
|
0.300 |
Biomarker
|
disease |
CTD_human |
Purification, properties, and immunotitration of hepatoma glutamine phosphoribosylpyrophosphate amidotransferase (amidophosphoribosyltransferase, EC 2.4.2.14).
|
761203 |
1979 |
|
Hepatoma, Novikoff
|
0.300 |
Biomarker
|
disease |
CTD_human |
Purification, properties, and immunotitration of hepatoma glutamine phosphoribosylpyrophosphate amidotransferase (amidophosphoribosyltransferase, EC 2.4.2.14).
|
761203 |
1979 |
|
Liver Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Purification, properties, and immunotitration of hepatoma glutamine phosphoribosylpyrophosphate amidotransferase (amidophosphoribosyltransferase, EC 2.4.2.14).
|
761203 |
1979 |
|
Experimental Hepatoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Purification, properties, and immunotitration of hepatoma glutamine phosphoribosylpyrophosphate amidotransferase (amidophosphoribosyltransferase, EC 2.4.2.14).
|
761203 |
1979 |
|
Liver neoplasms
|
0.210 |
AlteredExpression
|
group |
BEFREE |
The cDNA of human amidophosphoribosyltransferase (EC 2.4.2.14, ATase), which is the supposed regulatory allosteric enzyme of de novo purine nucleotide biosynthesis, has been cloned from human hepatoma (HepG2) cDNA library.
|
8380692 |
1993 |
|
Liver carcinoma
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
The cDNA of human amidophosphoribosyltransferase (EC 2.4.2.14, ATase), which is the supposed regulatory allosteric enzyme of de novo purine nucleotide biosynthesis, has been cloned from human hepatoma (HepG2) cDNA library.
|
8380692 |
1993 |
|
Liver neoplasms
|
0.210 |
Biomarker
|
group |
RGD |
Enzymic capacities of purine de Novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues.
|
6327016 |
1984 |
|
Liver carcinoma
|
0.210 |
Biomarker
|
disease |
RGD |
The purine phosphoribosyltransferase activities were also higher than that of amidophosphoribosyltransferase in Lewis lung carcinoma (8.2- to 32-fold), human renal cell carcinoma (3.5- to 22-fold), and hepatocellular carcinoma (3.4- to 30-fold).
|
6327016 |
1984 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Renal hypertrophy in experimental diabetes. The activity of the 'de novo' and salvage pathways of purine [corrected] synthesis.
|
2451505 |
1988 |
|
Hepatoblastoma
|
0.200 |
Biomarker
|
disease |
RGD |
Enzymic capacities of purine de Novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues.
|
6327016 |
1984 |
|
Malignant neoplasm of liver
|
0.200 |
Biomarker
|
disease |
RGD |
Enzymic capacities of purine de Novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues.
|
6327016 |
1984 |
|
Hepatoblastoma Caused By Somatic Mutation
|
0.200 |
Biomarker
|
disease |
RGD |
Enzymic capacities of purine de Novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues.
|
6327016 |
1984 |
|
Renal Cell Carcinoma
|
0.200 |
Biomarker
|
disease |
RGD |
Glutamine-phosphoribosylpyrophosphate amidotransferase (amidophosphoribosyltransferase, EC 2.4.2.14) activity in normal, differentiating, and neoplastic kidney.
|
476627 |
1979 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we show AZIN1 and PPAT are direct ERα targets that are essential for BCa cell survival and growth.
|
30463022 |
2018 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we show AZIN1 and PPAT are direct ERα targets that are essential for BCa cell survival and growth.
|
30463022 |
2018 |
|
Alcoholic Intoxication, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The activity of XO and ADA increased, and their mRNA expression was enhanced in the alcohol dependence group, but there was no significant difference in the activity of RPPPK and GPRPPAT in the liver, small intestine, and muscle; furthermore, no significant difference in the activity of HGPRT and APRT was observed in the brain.
|
27838211 |
2017 |
|
Colorectal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to identify whether somatic mutations in OGDH, PPAT and PCCA genes known to be involved in amino acid or nucleotide metabolism are mutated in gastric cancer (GC) and colorectal cancer (CRC).
|
27468871 |
2016 |
|
Malignant neoplasm of stomach
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to identify whether somatic mutations in OGDH, PPAT and PCCA genes known to be involved in amino acid or nucleotide metabolism are mutated in gastric cancer (GC) and colorectal cancer (CRC).
|
27468871 |
2016 |
|
Stomach Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to identify whether somatic mutations in OGDH, PPAT and PCCA genes known to be involved in amino acid or nucleotide metabolism are mutated in gastric cancer (GC) and colorectal cancer (CRC).
|
27468871 |
2016 |
|
Ovarian Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirteen variants in the pyrimidine metabolism genes, DPYD, DPYS, PPAT, and TYMS, also interacted significantly with folate in a multivariant analysis (corrected p = 9.9 × 10⁻⁶) but collectively explained only 0.2% of OC risk.
|
25066213 |
2014 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirteen variants in the pyrimidine metabolism genes, DPYD, DPYS, PPAT, and TYMS, also interacted significantly with folate in a multivariant analysis (corrected p = 9.9 × 10⁻⁶) but collectively explained only 0.2% of OC risk.
|
25066213 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirteen variants in the pyrimidine metabolism genes, DPYD, DPYS, PPAT, and TYMS, also interacted significantly with folate in a multivariant analysis (corrected p = 9.9 × 10⁻⁶) but collectively explained only 0.2% of OC risk.
|
25066213 |
2014 |